Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

22 Jun 2015

Abstract excerpt

Metaplastic breast carcinoma (MBC) is a rare histological breast cancer subtype characterized by mesenchymal elements and poor clinical outcome. A large fraction of MBCs harbor defects in breast cancer 1 (BRCA1). As BRCA1 deficiency sensitizes tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (PARP) inhibitors, we sought to investigate the response of BRCA1-deficient MBCs to the PARP inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Metabolism, Diabetes, and Cancer
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26100884
DOI: 10.1073/pnas.1500223112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancerPMID 26100884Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanSemantic proximity Read ↗

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.Semantic proximity Read ↗

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapiesSemantic proximity Read ↗

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast CancerSemantic proximity Read ↗

Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancerSemantic proximity Read ↗

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumoursSemantic proximity Read ↗

A phenotypic mouse model of basaloid breast tumors.Semantic proximity Read ↗

A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian CarcinomaSemantic proximity Read ↗

Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancerSemantic proximity Read ↗

Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter MouseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.